Carlos Perez, MD, an internationally renowned cancer researcher and professor emeritus of radiation oncology at Washington University in St. Louis, died Aug. 21 at 88.
Uncategorized
Almost nothing that we view as modern cardiology was available 50 years ago. Cardiac procedures and surgery, cardiac intensive care units, almost all cardiovascular medications and even cardiology as a specialty were either unknown or very early in development in…
Newark, Del.-based ChristianaCare will use a $1 million donation to purchase a radiography system for breast cancer detection at the Helen F. Graham Cancer Center & Research Institute, according to an Aug. 31 report from the Delaware Business Times.
A swath of anti-LGBTQ bills that have moved through the Louisiana legislature throughout 2023 prompted Jake Kleinmahon, MD — one of only a few pediatric cardiologists in the state who handle heart transplants — to depart the state with his…
Marlex Pharmaceuticals recalled two lots of digoxin tablets, which are used to treat heart failure, because of swapped labels for the 0.25 milligram and 0.125 milligram solutions, the FDA said Aug. 31.
Advertisement
Though COVID-19 deaths among the general population were lower during the winter omicron surge compared to the preceding winter, the death rate for cancer patients was higher, according to a study published Aug. 31 in JAMA Oncology.
Columbus-based Ohio State University's Wexner Medical Center was the first participant in a trial to test a new device to treat heart failure symptoms, according to an Aug. 31 news release.
The Biden administration shared details about its new program as part of the Cancer Moonshot project, which will aim to build robust mRNA platforms that can "to train the immune system to more effectively fight cancer and other diseases," according…
Rochester, Minn.-based Mayo Clinic Hospital, New York City-based NYU Langone Hospitals and Murray, Utah-based Intermountain Medical Center tied for the lowest death rate for heart attack patients in the country, according to CMS data.
The oral drug muvalaplin saw positive results in the first phase 1 study involving health participants for lipoprotein, a genetic marker for cardiovascular disease that's known for "sticky" cholesterol.